Search

Solid polymer electrolytes (SPEs) that can offer flexible processability, highly tunable chemical functionality, and cost effectiveness are regarded as attractive alternatives for liquid electrolytes (LE) to address their safety and energy density limitations. However, it remains a great challenge for SPEs to stabilize Li+ deposition at the electrolyte–electrode interface and impede lithium dendrite proliferation compared with LE‐based systems. Herein, a design of solid‐state fluorinated bifunctional SPE (FB‐SPE) that covalently tethers fluorinated chains with polyether‐based segments is proposed and synthesized via photo‐controlled radical polymerization (photo‐CRP). In contrast to the conventional non‐fluorinated polyether‐derived SPEs, FB‐SPE is able to provide conducting Li+ transport pathways up to ≈5.0 V, while simultaneously forming a LiF interaction that can enhance Li anode compatibility and prevent Li dendrites growth. As a result, the FB‐SPE exhibits outstanding cycling stability in Li||Li symmetrical cells of over 1500 operating hours at as high current density as 0.2 mA cm−2. A thin and uniform Li deposition layer and LiF‐rich SEI at the surface of Li anode are found, and stable cycling with average coulombic efficiencies of 99% is demonstrated in Li||LFP and Li||NCM all‐solid‐state batteries based on such bifunctional fluorinated SPEs. The interesting fluorine effect and effective self‐suppression of lithium dendrites will inform rational molecular design of novel electrolytes and practical development of all‐solid‐state Li metal batteries. [ABSTRACT FROM AUTHOR]

Mycoplasma pneumoniae is a leading cause of community-acquired respiratory infections. Infantile Feire Kechuan Oral Solution (IFKOS) is effective for treatment of M. pneumoniae infection. The aim of this study was to explore the potential mechanism of IFKOS against M. pneumoniae infection in basal epithelial human lung adenocarcinoma A549 cells. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was used to determine the effects of IFKOS on the viability of A549 cells infected with M. pneumoniae. Optical microscopy was used to observe cell morphology and a Muse cell analyzer was used to assess apoptosis and the cell cycle phase. Enzyme-linked immunosorbent assays were employed to assess the expression levels of interleukin (IL)-4, IL-6, IL-8, IL-17, tumor necrosis factor (TNF)-α, interferon (IFN)-α, and IFN-γ. Under certain conditions, M. pneumoniae infection reduced the viability and inhibited the proliferation of A549 cells, promoted early apoptosis, and arrested cells in the G0/G1 phase, thus shortening the S and G2/M phases (all p < 0.05). M. pneumoniae also upregulated expression of IL-8 and TNF-α and downregulated that of IL-6 (p < 0.05), which switched the immune balance of Th1/Th2 to Th1 cells. IFKOS (5.531 mg/mL) improved the viability and proliferation of M. pneumoniae -infected A549 cells, mitigated early apoptosis, and reversed cell cycle arrest in the G0/G1 phase, thereby extending the S and G2/M phases (all, p < 0.05). IFKOS downregulated expression of IL-8 and TNF-α and upregulated that of IL-6 (p < 0.01), thereby reversing the immune imbalance of Th1/Th2. Secretion of IL-4, IL-17, IFN-α, and IFN-γ was not observed. IFKOS played a protective role in the regulation of cell viability, apoptosis, the cell cycle, and Th1/Th2 immune imbalance induced by M. pneumoniae infection and conveyed an anti-inflammatory effect in A549 cells. • Mycoplasma pneumoniae is an important pathogen of community-acquired pneumonia in children. • Infantile Feire Kechuan Oral Solution (IFKOS) is effective for treatment of Mycoplasma pneumoniae pneumonia. • M. pneumoniae reduced the viability of A549 cells, promoted apoptosis, arrested cell cycle, and disordered cytokines. • IFKOS improved the viability of M. pneumoniae -infected A549 cells, mitigated apoptosis, reversed cell cycle arrest, and regulated cytokines. [ABSTRACT FROM AUTHOR]

Bruton's tyrosine kinase (BTK) has emerged as a promising drug target for multiple diseases, particularly haematopoietic malignancies and autoimmune diseases related to B lymphocytes. This review focuses on the diverse, small-molecule inhibitors of BTK kinase that have shown good prospects for clinical application. Individual examples of these inhibitors, including both reversible and irreversible inhibitors and a recently developed reversible covalent inhibitor of BTK, are discussed. Considerable progress has been made in the development of irreversible inhibitors, most of which target the SH3 pocket and the cysteine 481 residue of BTK. The present review also surveys the pharmacological advantages and deficiencies of both reversible and irreversible BTK drugs, with a focus on the structure-activity relationship (SARs) and binding modes of representative drugs, which could inspire critical thinking and new ideas for developing potent BTK inhibitors with less unwanted off-target effects. [ABSTRACT FROM AUTHOR]

Fourteen bergenin/cinnamic acid hybrids were synthesized, characterized and evaluated for their antitumour activity both in vitro and in vivo . The most potent compound, 5c, arrested HepG2 cells (IC 50 = 4.23 ± 0.79 μM) in the G2/M phase and induced cellular apoptosis. Moreover, compound 5c was also found to suppress the tumour growth in Heps xenograft-bearing mice with low toxicity. In the mechanistic study, 5c administration ignited a mitochondria-mediated apoptosis pathway of HepG2 cell death. Furthermore, 5c activated Akt-dependent pathways and further decreased the expression of the Bcl-2 family of proteins. The downstream mitochondrial p53 translocation was also significantly activated, accompanied by an increase of the caspase-9, caspase-3 activation. These data imply that bergenin/cinnamic acid hybrids could serve as novel Akt/Bcl-2 inhibitors for further preclinical studies. [ABSTRACT FROM AUTHOR]

The widespread nature of several viruses is greatly credited to their rapidly altering RNA genomes that enable the infection to persist despite challenges presented by host cells. Within the RNA genome of infections is RNA-dependent RNA polymerase (RdRp), which is an essential enzyme that helps in RNA synthesis by catalysing the RNA template-dependent development of phosphodiester bonds. Therefore, RdRp is an important therapeutic target in RNA virus-caused diseases, including SARS-CoV-2. In this review, we describe the promising RdRp inhibitors that have been launched or are currently in clinical studies for the treatment of RNA virus infections. Structurally, nucleoside inhibitors (NIs) bind to the RdRp protein at the enzyme active site, and nonnucleoside inhibitors (NNIs) bind to the RdRp protein at allosteric sites. By reviewing these inhibitors, more precise guidelines for the development of more promising anti-RNA virus drugs should be set, and due to the current health emergency, they will eventually be used for COVID-19 treatment. Image 1 • This article provides an overview of RdRp inhibitors that have been launched or are in clinical studies for the treatment of RNA virus infections, including COVID-19. • Nucleoside inhibitors (NIs) exhibit broad-spectrum antiviral activity but pose a more serious toxicity risk than non-nucleoside inhibitors (NNIs) because high dosages of NIs result in accumulation in plasma. • Structurally diverse NNIs are endowed with high potential activities but tend to induce drug resistance due to the RdRp allosteric site. [ABSTRACT FROM AUTHOR]